Skip to main content
SpringerLink
Log in

Expression of CD44 Isoforms in Human Colorectal Cancer Cell Lines

  • MEDICAL BIOTECHNOLOGY
  • Published:
Applied Biochemistry and Microbiology Aims and scope Submit manuscript

Abstract

The expression profile of CD44 isoforms in 55 colorectal cancer (CRC) cell lines has been evaluated based on mRNA sequencing data from the Cancer Cell Line Encyclopedia database. The distribution of CD44 mRNA isoforms differs significantly between CRC lines. In 13 studied lines, including Caco-2 and RKO, CD44 expression was not detected. In most other lines, isoform 3 of CD44 mRNA was the most abundant; however, the level of its expression varied and it was absent in the MDST8 and SNU503 lines. The highest level of isoform 3 was observed in CW2 and T84 lines. The next most frequent was isoform 4 with its expression level being lower than that of isoform 3, except for the HCT116, SNU81, NCIH508 and SNUC4 lines. The highest expression of isoform 4 was detected in the MDST8 line, the only line in which isoform 6 was also expressed. Isoform 2 was also present in CRC cell lines; its highest expression level was found in the SNU503 line. Isoforms 1, 5, and 7 were not expressed in any of the studied lines. It is necessary to take into account the mRNA expression profile of specific CD44 isoforms when choosing a cell model to study its role in CRC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.

Similar content being viewed by others

REFERENCES

  1. Bray, F., Ferlay, J., Soerjomataram, I., et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 2018, vol. 68, pp. 394–424. https://doi.org/10.3322/caac.21492

    Article  Google Scholar 

  2. Van Cutsem E., Cervantes A., Nordlinger B., Arnold D., ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2014, vol. 25, suppl. 3, pp. iii1–9. https://doi.org/10.1093/annonc/mdu260

    Article  Google Scholar 

  3. Weiser, M.R., AJCC 8th ed.: Colorectal cancer. Ann. Surg. Oncol., 2018, vol. 25, pp. 1454–1455. https://doi.org/10.1245/s10434-018-6462-1

  4. Munro, M.J., Wickremesekera, S.K., Peng, L., et al., Cancer stem cells in colorectal cancer: a review, J. Clin. Pathol., 2018, vol. 71, pp. 110–116. https://doi.org/10.1136/jclinpath-2017-204739

    Article  CAS  Google Scholar 

  5. Wang, Z., Tang, Y., Xie, L., et al., The prognostic and clinical value of CD44 in colorectal cancer: a metaanalysis, Front. Oncol., 2019, vol. 9, p. 309. https://doi.org/10.3389/fonc.2019.00309

    Article  Google Scholar 

  6. Chen, J., Zhou, J., Lu, J., et al., Significance of CD44 expression in head and neck cancer: a systemic review and meta-analysis, BMC Cancer, 2014, vol. 14, pp. 15. https://doi.org/10.1186/1471-2407-14-15

    Article  Google Scholar 

  7. Luo, Y. and Tan, Y., Prognostic value of CD44 expression in patients with hepatocellular carcinoma: meta-analysis, Cancer Cell Int., 2016, vol. 16, p. 47. https://doi.org/10.1186/s12935-016-0325-2

    Article  CAS  Google Scholar 

  8. Li, X., Ma, X., Chen, L., et al., Prognostic value of CD44 expression in renal cell carcinoma: a systematic review and meta-analysis, Sci. Rep., 2015, vol. 5, p. 13157. https://doi.org/10.1038/srep13157

    Article  CAS  Google Scholar 

  9. Lin, J. and Ding, D., The prognostic role of the cancer stem cell marker CD44 in ovarian cancer: a meta-analysis, Cancer Cell Int., 2017, vol. 17, p. 8. https://doi.org/10.1186/s12935-016-0376-4

    Article  Google Scholar 

  10. Chen, Y., Fu, Z., Xu, S., et al., The prognostic value of CD44 expression in gastric cancer: a meta-analysis, Biomed. Pharmacother., 2014, vol. 68, pp. 693–697. https://doi.org/10.1016/j.biopha.2014.08.001

    Article  CAS  Google Scholar 

  11. Screaton, G.R., Bell, M.V., Jackson, D.G., et al., Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons, Proc. Natl. Acad. Sci. U. S. A., 1992, vol. 89, pp. 12160–12164. https://doi.org/10.1073/pnas.89.24.12160

    Article  CAS  Google Scholar 

  12. Azevedo, R., Gaiteiro, C., Peixoto, A., et al., CD44 glycoprotein in cancer: a molecular conundrum hampering clinical applications, Clin. Proteomics, 2018, vol. 15, p. 22. https://doi.org/10.1186/s12014-018-9198-9

    Article  CAS  Google Scholar 

  13. Ponta, H., Sherman, L., and Herrlich, P.A., CD44: from adhesion molecules to signalling regulators, Nat. Rev. Mol. Cell Biol., 2003, vol. 4, pp. 33–45. https://doi.org/10.1038/nrm1004

    Article  CAS  Google Scholar 

  14. Zöller, M., CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?, Nat. Rev. Cancer, 2011, vol. 11, pp. 254–267. https://doi.org/10.1038/nrc3023

    Article  CAS  Google Scholar 

  15. Xu, H., Niu, M., Yuan, X., et al., CD44 as a tumor biomarker and therapeutic target, Exp. Hematol. Oncol., 2020, vol. 9, p. 36. https://doi.org/10.1186/s40164-020-00192-0

    Article  CAS  Google Scholar 

  16. Bhattacharya, R., Mitra, T., Ray Chaudhuri, S., and Roy, S.S., Mesenchymal splice isoform of CD44 (CD44s) promotes EMT/invasion and imparts stem-like properties to ovarian cancer cells, J. Cell. Biochem., 2018, vol. 119, pp. 3373–3383. https://doi.org/10.1002/jcb.26504

    Article  CAS  Google Scholar 

  17. Skandalis, S.S., Karalis, T.T., Chatzopoulos, A., and Karamanos, N.K. Hyaluronan–CD44 axis orchestrates cancer stem cell functions, Cell. Signal., 2019, vol. 63, pp. 109377. https://doi.org/10.1016/j.cellsig.2019.109377

    Article  CAS  Google Scholar 

  18. Ghandi, M., Huang, F.W., Jané-Valbuena, J., et al., Next-generation characterization of the Cancer Cell Line Encyclopedia, Nature, 2019, vol. 569, pp. 503–508. https://doi.org/10.1038/s41586-019-1186-3

    Article  CAS  Google Scholar 

  19. Ward, J.H., Hierarchical grouping to optimize an objective function, J. Am. Stat. Assoc., 1963, vol. 58, pp. 236–244. https://doi.org/10.2307/2282967

    Article  Google Scholar 

  20. Waskom, M.L., (n. d.) seaborn: statistical data visualization, J. Open Source Software, 2021, vol. 6, pp. 3021. https://doi.org/10.21105/joss.03021

    Article  Google Scholar 

  21. Brown, T.A., Bouchard, T., St John, T., et al., Human keratinocytes express a new CD44 core protein (CD44E) as a heparan-sulfate intrinsic membrane proteoglycan with additional exons, J. Cell Biol., 1991, vol. 113, pp. 207–221. https://doi.org/10.1083/jcb.113.1.207

    Article  CAS  Google Scholar 

  22. Naor, D., Nedvetzki, S., Golan, I., et al., CD44 in cancer, Crit. Rev. Clin. Lab. Sci., 2002, vol. 39, pp. 527–579. https://doi.org/10.1080/10408360290795574

    Article  CAS  Google Scholar 

  23. Suwannakul, N., Ma, N., Thanan, R., et al., Overexpression of CD44 variant 9: a novel cancer stem cell marker in human cholangiocarcinoma in relation to inflammation, Mediat. Inflamm., 2018, vol. 1–8. https://doi.org/10.1155/2018/4867234

  24. Suwannakul, N., Ma, N., Midorikawa, K., et al., CD44v9 induces stem cell-like phenotypes in human cholangiocarcinoma, Front. Cell Dev. Biol., 2020, vol. 8, p. 417. https://doi.org/10.3389/fcell.2020.00417

    Article  Google Scholar 

  25. Taniguchi, D., Saeki, H., Nakashima, Y., et al., CD44v9 is associated with epithelial-mesenchymal transition and poor outcomes in esophageal squamous cell carcinoma, Cancer Med., 2018, vol. 7, pp. 6258–6268. https://doi.org/10.1002/cam4.1874

    Article  CAS  Google Scholar 

Download references

Funding

The study was funded by the Russian Science Foundation (project no. 17-14-01338).

Author information

Authors and Affiliations

  1. Bioclinicum Scientific Research Center, 115088, Moscow, Russia

    M. P. Raigorodskaya, S. A. Tonevitskaya & D. V. Maltseva

  2. Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997, Moscow, Russia

    V. O. Novosad

  3. Faculty of Biology and Biotechnology, Higher School of Economics, Moscow National Research University, 117312, Moscow, Russia

    S. A. Tonevitskaya

Authors
  1. M. P. Raigorodskaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. O. Novosad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. A. Tonevitskaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. V. Maltseva
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. V. Maltseva.

Ethics declarations

The authors declare that they have no conflicts of interest.

This article does not contain any studies involving animals performed by any of the authors.

This article does not contain any studies involving human participants performed by any of the authors outside the scope of their normal professional activities.

Additional information

Translated by I. Gordon

Abbreviations: CCLE, Cancer Cell Line Encyclopedia; CD44s, CD44 standard isoform; CRC, colorectal cancer; CSC, cancer stem cells.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Raigorodskaya, M.P., Novosad, V.O., Tonevitskaya, S.A. et al. Expression of CD44 Isoforms in Human Colorectal Cancer Cell Lines. Appl Biochem Microbiol 58, 992–996 (2022). https://doi.org/10.1134/S0003683822090071

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S0003683822090071

Keywords:

Search

Navigation